VJHemOnc was the official media partner for the recent 2nd International PNH Interest Group (IPIG) Conference held in Paris, France. In today’s podcast episode, you will hear some highlights from the event from leading experts in the field of paroxysmal nocturnal hemoglobinuria (PNH).
First, Jens Panse, MD, Aachen University Hospital, Aachen, Germany, Richard Kelly, MBChB, PhD, St James’s University Hospital, Leeds, UK, and Benjamin Chin-Yee, MD, MA, FRCPC, Western University, London, Canada, provide insight into challenging situations in the current era of PNH treatment, including switching from anti-C5 to proximal complement inhibition, discontinuing anticoagulation, and the management of pregnant patients with PNH. Following this, Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, discusses the role of ravulizumab in this disease, and Dr Kelly and Catherine Flynn, MD, St James’s Hospital, Dublin, Ireland, outline findings from the COMMODORE 1 and 2 trials. Finally, Jeff Szer, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the clinical problem of thrombosis in patients with PNH, highlighting how this complication can be prevented.
The post IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more appeared first on VJHemOnc.
